Proof Shorts Lieing " Securing Approval for a Promising Drug,,Path to Solid Profits for Investors" LINK
Seeking Alpha By: Helix Investment Managment
12/19/12 Updated From 11/28/12
NuPathe has addressed each aspect of the FDA's concerns regarding Zecuity. It conducted a second safety trial, redesigned the patch itself, conducted a new usability study to show that patients can correctly use the drug during migraines, and addressed the FDA's other concerns. While approval of Zecuity is not guaranteed, we believe that NuPathe has a solid chance at securing approval for what looks to be a promising drug. Shares of NuPathe offer a potential path to solid profits.